The Centiloid Project: Standardizing Quantitative Amyloid Plaque Estimation by PET

Overview

Journal Alzheimers Dement

Specialties Neurology
Psychiatry

Date 2014 Dec 3

PMID 25443857

Citations 483

Authors

William E Klunk

Robert A Koeppe

Julie C Price

Tammie L Benzinger

Michael D Devous Sr

William J Jagust

Keith A Johnson

Chester A Mathis

Davneet Minhas

Michael J Pontecorvo

Christopher C Rowe

Daniel M Skovronsky

Mark A Mintun

Affiliations

Soon will be listed here.

Abstract

Although amyloid imaging with PiB-PET ([C-11]Pittsburgh Compound-B positron emission tomography), and now with F-18-labeled tracers, has produced remarkably consistent qualitative findings across a large number of centers, there has been considerable variability in the exact numbers reported as quantitative outcome measures of tracer retention. In some cases this is as trivial as the choice of units, in some cases it is scanner dependent, and of course, different tracers yield different numbers. Our working group was formed to standardize quantitative amyloid imaging measures by scaling the outcome of each particular analysis method or tracer to a 0 to 100 scale, anchored by young controls (≤ 45 years) and typical Alzheimer's disease patients. The units of this scale have been named "Centiloids." Basically, we describe a "standard" method of analyzing PiB PET data and then a method for scaling any "nonstandard" method of PiB PET analysis (or any other tracer) to the Centiloid scale.

Citing Articles

Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers.

Thal D, Poesen K, Vandenberghe R, De Meyer S Mol Neurodegener. 2025; 20(1):33.

PMID: 40087672 DOI: 10.1186/s13024-025-00819-y.

Clinical Importance of Amyloid Beta Implication in the Detection and Treatment of Alzheimer's Disease.

Pokrzyk J, Kulczynska-Przybik A, Guzik-Makaruk E, Winkel I, Mroczko B Int J Mol Sci. 2025; 26(5).

PMID: 40076562 PMC: 11900921. DOI: 10.3390/ijms26051935.

Comparison of plasma p-tau217 and p-tau181 in predicting amyloid positivity and prognosis among Korean memory clinic patients.

Kwon H, Hwang M, Koh S, Choi S, Lee J, Kim H Sci Rep. 2025; 15(1):7791.

PMID: 40044785 PMC: 11882798. DOI: 10.1038/s41598-025-90232-8.

Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.

Leuzy A, Bollack A, Pellegrino D, Teunissen C, La Joie R, Rabinovici G Alzheimers Dement. 2025; 21(3):e14528.

PMID: 40042435 PMC: 11881640. DOI: 10.1002/alz.14528.

Association between BrainAGE and Alzheimer's disease biomarkers.

Abughofah Y, Deardorff R, Vosmeier A, Hottle S, Dage J, Dempsey D Alzheimers Dement (Amst). 2025; 17(1):e70094.

PMID: 40018325 PMC: 11865712. DOI: 10.1002/dad2.70094.

References

Oh H, Madison C, Haight T, Markley C, Jagust W . Effects of age and β-amyloid on cognitive changes in normal elderly people. Neurobiol Aging. 2012; 33(12):2746-55. PMC: 3381075. DOI: 10.1016/j.neurobiolaging.2012.02.008. View

Klunk W, Price J, Mathis C, Tsopelas N, Lopresti B, Ziolko S . Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007; 27(23):6174-84. PMC: 3265970. DOI: 10.1523/JNEUROSCI.0730-07.2007. View

Morris J, Aisen P, Bateman R, Benzinger T, Cairns N, Fagan A . Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond). 2012; 2(10):975-984. PMC: 3489185. DOI: 10.4155/cli.12.93. View

Tolboom N, Yaqub M, Boellaard R, Luurtsema G, Windhorst A, Scheltens P . Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2009; 36(10):1629-38. PMC: 2758198. DOI: 10.1007/s00259-009-1129-6. View

Mintun M, Larossa G, Sheline Y, Dence C, Lee S, Mach R . [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006; 67(3):446-52. DOI: 10.1212/01.wnl.0000228230.26044.a4. View

Aizenstein H, Nebes R, Saxton J, Price J, Mathis C, Tsopelas N . Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008; 65(11):1509-17. PMC: 2636844. DOI: 10.1001/archneur.65.11.1509. View

Yamane T, Ikari Y, Nishio T, Ishii K, Kato T, Ito K . Visual-statistical interpretation of (18)F-FDG-PET images for characteristic Alzheimer patterns in a multicenter study: inter-rater concordance and relationship to automated quantitative evaluation. AJNR Am J Neuroradiol. 2013; 35(2):244-9. PMC: 7965770. DOI: 10.3174/ajnr.A3665. View

Rowe C, Ng S, Ackermann U, Gong S, Pike K, Savage G . Imaging beta-amyloid burden in aging and dementia. Neurology. 2007; 68(20):1718-25. DOI: 10.1212/01.wnl.0000261919.22630.ea. View

Chien D, Bahri S, Szardenings A, Walsh J, Mu F, Su M . Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2012; 34(2):457-68. DOI: 10.3233/JAD-122059. View

10.

Morris J . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43(11):2412-4. DOI: 10.1212/wnl.43.11.2412-a. View

11.

Jack Jr C, Barkhof F, Bernstein M, Cantillon M, Cole P, DeCarli C . Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement. 2011; 7(4):474-485.e4. PMC: 3396131. DOI: 10.1016/j.jalz.2011.04.007. View

12.

Jagust W, Bandy D, Chen K, Foster N, Landau S, Mathis C . The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010; 6(3):221-9. PMC: 2920531. DOI: 10.1016/j.jalz.2010.03.003. View

13.

Rabinovici G, Furst A, ONeil J, Racine C, Mormino E, Baker S . 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007; 68(15):1205-12. DOI: 10.1212/01.wnl.0000259035.98480.ed. View

14.

Morris J, Roe C, Xiong C, Fagan A, Goate A, Holtzman D . APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010; 67(1):122-31. PMC: 2830375. DOI: 10.1002/ana.21843. View

15.

Boccardi M, Bocchetta M, Ganzola R, Robitaille N, Redolfi A, Duchesne S . Operationalizing protocol differences for EADC-ADNI manual hippocampal segmentation. Alzheimers Dement. 2013; 11(2):184-94. DOI: 10.1016/j.jalz.2013.03.001. View

16.

Ashburner J . A fast diffeomorphic image registration algorithm. Neuroimage. 2007; 38(1):95-113. DOI: 10.1016/j.neuroimage.2007.07.007. View

17.

Frisoni G, Bocchetta M, Chetelat G, Rabinovici G, de Leon M, Kaye J . Imaging markers for Alzheimer disease: which vs how. Neurology. 2013; 81(5):487-500. PMC: 3776529. DOI: 10.1212/WNL.0b013e31829d86e8. View

18.

Okamura N, Furumoto S, Harada R, Tago T, Yoshikawa T, Fodero-Tavoletti M . Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013; 54(8):1420-7. DOI: 10.2967/jnumed.112.117341. View

19.

Ashburner J, Friston K . Nonlinear spatial normalization using basis functions. Hum Brain Mapp. 1999; 7(4):254-66. PMC: 6873340. View

20.

Herholz K, Salmon E, Perani D, Baron J, Holthoff V, Frolich L . Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002; 17(1):302-16. DOI: 10.1006/nimg.2002.1208. View